Literature DB >> 1688687

Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis.

P F Piguet1, G E Grau, P Vassalli.   

Abstract

Mouse recombinant tumor necrosis factor (TNF) (or its solvent alone as a control) was administered subcutaneously to mice by a cannula connected to an osmotic minipump. Perfusion at a rate of 35 ng/hr for seven days induced the formation of a tissue mass composed mainly of fibroblasts, collagen, and capillaries. Necrosis (apoptosis) of isolated fibroblasts was observed. Polymorphonuclear leukocytes were abundant after three to four days of perfusion but were absent later. The covering epidermis showed a hyperplastic reaction associated with necrosis of isolated keratinocytes. Perfusion at a rate of 170 ng/hr led, after four to five days, to a massive necrosis. Necrosis was completely prevented by rabbit anti-TNF IgG but not by anti-LPS IgG, irradiation, or administration of indomethacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688687      PMCID: PMC1877459     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

Review 1.  Tumor necrosis, cachexia, shock, and inflammation: a common mediator.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 2.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

3.  Influence of delayed immune reactions on human epidermal keratinocytes.

Authors:  G Kaplan; M D Witmer; I Nath; R M Steinman; S Laal; H K Prasad; E N Sarno; U Elvers; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

4.  Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.

Authors:  J E Talmadge; O Bowersox; H Tribble; S H Lee; H M Shepard; D Liggitt
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

5.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis.

Authors:  S M Laster; J G Wood; L R Gooding
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

6.  Induction of dermal and subcutaneous inflammation by recombinant cachectin/tumor necrosis factor (TNF alpha) in the mouse.

Authors:  R J Sharpe; R J Margolis; M Askari; E P Amento; R D Granstein
Journal:  J Invest Dermatol       Date:  1988-10       Impact factor: 8.551

7.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.

Authors:  J L Rothstein; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

8.  Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers.

Authors:  K H Sprugel; J M McPherson; A W Clowes; R Ross
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

9.  Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity.

Authors:  D L Fraker; M C Stovroff; M J Merino; J A Norton
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Keratinocyte-derived tumor necrosis factor and the physiopathology of the skin.

Authors:  P F Piguet
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

4.  Transformation of fibroblasts into endothelial cells during angiogenesis.

Authors:  K Kon; T Fujiwara
Journal:  Cell Tissue Res       Date:  1994-12       Impact factor: 5.249

5.  Effects of tumour necrosis factor alpha on bone marrow aspirates of patients with acute myelogenous leukemia determined by flow-cytometric cell-cycle analysis.

Authors:  H D Kleine; U Wagner; H Poliwoda; M Freund
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Increased epidermal cell proliferation in normal human skin in vivo following local administration of interferon-gamma.

Authors:  J N Barker; J R Goodlad; E L Ross; C C Yu; R W Groves; D M MacDonald
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

7.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

8.  Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis.

Authors:  Y Miyazaki; K Araki; C Vesin; I Garcia; Y Kapanci; J A Whitsett; P F Piguet; P Vassalli
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Induction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chloride.

Authors:  R Beyaert; C De Potter; B Vanhaesebroeck; F Van Roy; W Fiers
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

10.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.